Title
Category
Credits
Event date
Cost
Essentials of Oncology Management for the Health Care Team
  • Transplantation
  • 6.00 ACPE - Pharmacists
  • 6.00 ACPE - Pharmacy Technicians
  • 6.00 AMA - Physicians
  • 6.00 ANCC - Nurses
  • 6.00 APA - Psychologists
  • 6.00 Attendance - General Attendance
  • 6.00 CCMC - General - Case Managers
  • 6.00 CDR - Dietitians
  • 6.00 ASWB - Social Workers
$0.00
Throughout these activities, faculty will discuss the keys to optimize the management/benefits of individuals with cancer. Participants will hear about current topics and exciting advances in the field of oncology.
Bladder Cancer Update: Advances in Treatment and the Role of Early Diagnosis
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.

Pages